Today Aker BioMarine employees were informed of the Company's intention to make
changes to Group financial reporting and legal entity structure. The
"Ingredients" and "Brands" financial reporting segments will be deconsolidated
into:

1. Feed Ingredients including Qrill Aqua and Pet, harvesting operations and
Uruguay distribution
2. Human Health Ingredients including Superba, Lysoveta and Houston
manufacturing
3. Consumer Health Products including Lang Pharma Nutrition, a premium private
label innovation and sales business in the US
4. Emerging Businesses including Epion Brands (Kori krill oil), Aion AS and
Understory Protein  

The new financial reporting and legal entity structure is meant to result in
better alignment between company strategy, operations, and financials, and to
improve transparency of business segments' earnings development. 

The Company will keep current external reporting structure through 2023, with
the new structures expected to be in place Q1 2024. Additional information will
be provided at the Q2 presentation on 14 July 2023.

For further information, please contact 
Christopher Robin Vinter, Investor Relations
Mobile: +47 911 60 820
Email:  Christopher.vinter@akerbiomarine.com  


This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.